“Samsung Biologics might become touchstone for financial reform”

It was argued that Samsung Biologics with accounting fraud and IPO legitimacy issues might become the ‘touchstone for financial reform.’

Won-Gu Ahn, former Director of the Daegu Regional Tax Service, expressed overall opinions about Samsung Biologics at a phone interview for the KBS’s morning news show called ‘Chegang Shisa.’

“Samsung Biologics listed stocks in 2016, but the company was evalu...